# Mark Gaffney

> Mark Gaffney is the Chief Executive Officer and Board member of Calluna Pharma, an Oslo-based clinical-stage biopharma chasing inflammatory and fibrotic disease by tuning the body's innate immune system. A mechanical engineer turned lawyer turned dealmaker, he spent two decades building and selling biotechs - Oxular went to Regeneron, Vedere Bio to Novartis - before taking the helm of a company born from the merger of Oxitope Pharma and Arxx Therapeutics and freshly backed by a 75 million euro Series A.

- **Role:** Chief Executive Officer & Board Member at Calluna Pharma
- **Organizations:** Calluna Pharma, Oxular Limited, Vedere Bio, Cyclerion Therapeutics, Ironwood Pharmaceuticals, U.S. Air Force
- **Nationality:** American
- **Education:** Mechanical Engineering, University of Pennsylvania, Juris Doctor (Law), Boston University
- **Known for:** Led Oxular Limited as CEO through its acquisition by Regeneron in late 2024, Served as CBO and COO of Vedere Bio through its acquisition by Novartis in late 2020, Over 20 years in corporate strategy, business development and operations across private and public biotech

## Career timeline

- **Earlier** — Served in U.S. Air Force intelligence
- **2000s-2010s** — Corporate development and operational roles at Ironwood Pharmaceuticals
- **2010s** — Corporate development and operations at Cyclerion Therapeutics
- **2020** — Chief Business Officer then Chief Operating Officer at Vedere Bio, acquired by Novartis
- **2024** — CEO of Oxular Limited, acquired by Regeneron; remains strategic advisor and board member
- **2024** — Appointed Chief Executive Officer & Board member of Calluna Pharma (October 2024)

## Achievements

- Led Oxular Limited as CEO through its acquisition by Regeneron in late 2024
- Served as CBO and COO of Vedere Bio through its acquisition by Novartis in late 2020
- Over 20 years in corporate strategy, business development and operations across private and public biotech
- Appointed CEO of Calluna Pharma as its lead candidate CAL101 entered the final stretch of Phase 1

## Latest updates

- **2024-10** — Appointed Chief Executive Officer and Board member of Calluna Pharma alongside Mark Altmeyer as Independent Chair.
- **2024-01** — Calluna Pharma closed a 75 million euro Series A financing led by investors including Forbion.

## Links

- Website: https://callunapharma.com
- LinkedIn: http://www.linkedin.com/in/mark-gaffney-b97a7812b

---

Profile page: https://yespress.io/mark-gaffney
Published by YesPress — https://yespress.io
Last updated: 2026-06-03